BACKGROUND: The aim of this study was to determine whether epicardial structural disease may affect the manifestation of a longitudinal decrease in myocardial blood flow (MBF) or MBF difference during hyperemia in cardiovascular risk individuals, and its dependency on the flow increase. METHODS AND RESULTS: In 54 cardiovascular risk individuals (at risk) and in 26 healthy controls, MBF was measured with (13)N-ammonia and PET/CT in mL/g/min at rest and during dipyridamole stimulation. Computed tomography coronary angiography (CTA) was performed using a 64-slice CT of a PET/CT system. Absolute MBFs during dipyridamole stimulation were mildly lower in the mid-distal than in the mid-LV myocardium in controls (2.20 ± .51 vs 2.29 ± .51, P < .0001), while it was more pronounced in at risk with normal and abnormal CTA (1.56 ± .42 vs 1.91 ± .46 and 1.18 ± .34 vs 1.51 ± .40 mL/g/min, respectively, P < .0001), resulting in a longitudinal MBF difference that was highest in at risk with normal CTA, intermediate in at risk abnormal CTA, and lowest in controls (.35 ± .16 and .22 ± .09 vs .09 ± .04 mL/g/min, respectively, P < .0001). On multivariate analysis, log-CCS and mid-LV hyperemic MBF increase, indicative of microvascular function, were independent predictors of the observed longitudinal MBF difference (P ≤ .004 by ANOVA). CONCLUSIONS: Epicardial structural disease and microvascular function are important determinants of an abnormal longitudinal MBF difference as determined with PET/CT.
BACKGROUND: The aim of this study was to determine whether epicardial structural disease may affect the manifestation of a longitudinal decrease in myocardial blood flow (MBF) or MBF difference during hyperemia in cardiovascular risk individuals, and its dependency on the flow increase. METHODS AND RESULTS: In 54 cardiovascular risk individuals (at risk) and in 26 healthy controls, MBF was measured with (13)N-ammonia and PET/CT in mL/g/min at rest and during dipyridamole stimulation. Computed tomography coronary angiography (CTA) was performed using a 64-slice CT of a PET/CT system. Absolute MBFs during dipyridamole stimulation were mildly lower in the mid-distal than in the mid-LV myocardium in controls (2.20 ± .51 vs 2.29 ± .51, P < .0001), while it was more pronounced in at risk with normal and abnormal CTA (1.56 ± .42 vs 1.91 ± .46 and 1.18 ± .34 vs 1.51 ± .40 mL/g/min, respectively, P < .0001), resulting in a longitudinal MBF difference that was highest in at risk with normal CTA, intermediate in at risk abnormal CTA, and lowest in controls (.35 ± .16 and .22 ± .09 vs .09 ± .04 mL/g/min, respectively, P < .0001). On multivariate analysis, log-CCS and mid-LV hyperemic MBF increase, indicative of microvascular function, were independent predictors of the observed longitudinal MBF difference (P ≤ .004 by ANOVA). CONCLUSIONS: Epicardial structural disease and microvascular function are important determinants of an abnormal longitudinal MBF difference as determined with PET/CT.
Authors: G D Hutchins; M Schwaiger; K C Rosenspire; J Krivokapich; H Schelbert; D E Kuhl Journal: J Am Coll Cardiol Date: 1990-04 Impact factor: 24.094
Authors: R Hachamovitch; D S Berman; L J Shaw; H Kiat; I Cohen; J A Cabico; J Friedman; G A Diamond Journal: Circulation Date: 1998-02-17 Impact factor: 29.690
Authors: T R DeGrado; M W Hanson; T G Turkington; D M Delong; D A Brezinski; J P Vallée; L W Hedlund; J Zhang; F Cobb; M J Sullivan; R E Coleman Journal: J Nucl Cardiol Date: 1996 Nov-Dec Impact factor: 5.952
Authors: Pascal Koepfli; Christophe A Wyss; Mehdi Namdar; Michael Klainguti; Gustav K von Schulthess; Thomas F Lüscher; Philipp A Kaufmann Journal: J Nucl Med Date: 2004-10 Impact factor: 10.057
Authors: Thomas H Schindler; Alvaro D Facta; John O Prior; Jerson Cadenas; Xiao-Li Zhang; Yanjie Li; James Sayre; Jonathan Goldin; Heinrich R Schelbert Journal: Eur J Nucl Med Mol Imaging Date: 2008-08-15 Impact factor: 9.236
Authors: Venkatesh L Murthy; Timothy M Bateman; Rob S Beanlands; Daniel S Berman; Salvador Borges-Neto; Panithaya Chareonthaitawee; Manuel D Cerqueira; Robert A deKemp; E Gordon DePuey; Vasken Dilsizian; Sharmila Dorbala; Edward P Ficaro; Ernest V Garcia; Henry Gewirtz; Gary V Heller; Howard C Lewin; Saurabh Malhotra; April Mann; Terrence D Ruddy; Thomas H Schindler; Ronald G Schwartz; Piotr J Slomka; Prem Soman; Marcelo F Di Carli; Andrew Einstein; Raymond Russell; James R Corbett Journal: J Nucl Cardiol Date: 2018-02 Impact factor: 5.952
Authors: Gabriella M Vincenti; Giuseppe Ambrosio; Jean-Noël Hyacinthe; Alessandra Quercioli; Yann Seimbille; François Mach; Osman Ratib; Jean-Paul Vallée; Thomas H Schindler Journal: J Nucl Cardiol Date: 2012-04-28 Impact factor: 5.952